Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: A randomized controlled trial

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 3, 2012, Pages 268-275

  Pan, Chang Yu ^a   Yang, Wenying ^b   Tou, Conrad ^c   Gause Nilsson, Ingrid ^d   Zhao, June ^c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

DPP 4 inhibitor; Glycaemic control; Incretins; Saxagliptin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SAXAGLIPTIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; COUGHING; DIABETIC PATIENT; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WAIST CIRCUMFERENCE;

ADAMANTANE; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PLACEBOS;

EID: 84863230449     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1306     Document Type: Article

References (25)

1. Donnelly R, Wang B, Qu X. Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments. Br J Clin Pharmacol 2006; 61(6): 702-705.
2. Chowdhury TA, Hitman GA. Type 2 diabetes in people of South Asian origin: potential strategies for prevention. Br J Diabetes Vasc Dis 2007; 7(6): 279-282.
3. Hossain P, Kawar B, Nahas ME. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007; 356(3): 213-215.
4. International Diabetes Federation. IDF Diabetes Atlas (4th edition), 2009. Available at: [7 July 2010].
5. Iwamoto Y, Kashiwagi A, Yamada N, et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 2010; 12(8): 700-708.
6. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010; 57(5): 383-394.
7. Nonaka K, Tsubouchi H, Okuyama K, Fukao Y, Johnson-Levonas AO, Amatruda JM. Effects of once-daily sitagliptin on 24-h glucose control following 4weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res 2009; 41(3): 232-237.
8. Mohan V, Yang W, Son H-Y, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009; 83(1): 106-116.
9. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696-1705.
10. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48(15): 5025-5037.
11. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; for the CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009; 25(10): 2401-2411.
12. DeFronzo RA, Hissa MN, Garber AJ, et al; for the Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32(9): 1649-1655.
13. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; and the CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63(9): 1395-1406.
14. Hollander P, Li J, Allen E, Chen R; for the CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94(12): 4810-4819.
15. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; for the CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11(6): 611-622.
16. Göke B, Gallwitz B, Eriksson J, Hellqvist Å, Gause-Nilsson I; for the D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010; 64(12): 1619-1631.
17. Scheen AJ, Charpentier G, Östgren CJ, Hellqvist Å, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010; 26(7): 540-549.
18. 1C conversion table. [14 November 2010].
19. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27(6): 1487-1495.
20. Chuang L-M, Tsai ST, Huang BY, Tai TY; on behalf of the Diabcare-Asia 1998 Study Group. The status of diabetes control in Asia-a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabet Med 2002; 19(12): 978-985.
21. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-1053.
22. Chan JCN, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301(20): 2129-2140.
23. International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. International Diabetes Federation: Brussels, 2005. [7 July 2010].
24. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15(6): 540-559.
25. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; for the Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29(12): 2632-2637.